ValiRx (LSE:VAL) Total Assets

: £4.07 Mil (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

ValiRx's Total Assets for the quarter that ended in Jun. 2023 was £4.07 Mil.

During the past 12 months, ValiRx's average Total Assets Growth Rate was 9.60% per year. During the past 3 years, the average Total Assets Growth Rate was -7.70% per year. During the past 5 years, the average Total Assets Growth Rate was -8.20% per year. During the past 10 years, the average Total Assets Growth Rate was -1.30% per year.

During the past 13 years, ValiRx's highest 3-Year average Total Assets Growth Rate was 129.80%. The lowest was -10.00%. And the median was 9.85%.

Total Assets is connected with ROA %. ValiRx's annualized ROA % for the quarter that ended in Jun. 2023 was -51.44%. Total Assets is also linked to Revenue through Asset Turnover. ValiRx's Asset Turnover for the quarter that ended in Jun. 2023 was 0.00.

ValiRx Total Assets Historical Data

The historical data trend for ValiRx's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

4.24

3.61

4.94

3.52

3.98

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Assets																4.15	3.52	3.00	3.98	4.07

ValiRx Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

ValiRx's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	3.826	+	0.15
	=	3.98

ValiRx's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	3.953	+	0.12
	=	4.07

ValiRx (LSE:VAL) Total Assets Explanation

Total Assets is connected with ROA %.

ValiRx's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	-2.07	/	( (3.976	+	4.072)	/ 2 )
	=	-2.07	/	4.024
	=	-51.44 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

ValiRx's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	0	/	( (3.976	+	4.072)	/ 2 )
=	0	/	4.024
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

ValiRx Total Assets Related Terms

Thank you for viewing the detailed overview of ValiRx's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.